Porton Pharma Solutions Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Nianfeng Ju

Chief executive officer

CN¥1.9m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	10.8%
Management average tenure	2.6yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

CEO

Nianfeng Ju (52 yo)

no data

Tenure

CN¥1,931,300

Compensation

Mr. Nianfeng Ju serves as General Manager of Porton Imp & Exp Ltd. Nianfeng Ju served as the General Manager of Porton Co., Ltd. He serves as a General Manager of Porton Pharma Solutions Ltd.Mr. Ju serves...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.8% CN¥ 1.0b
Hui Chen	Deputy GM & CFO	2.6yrs	CN¥1.59m	no data
Yinchun Bai	Senior Deputy GM & COO	2.6yrs	CN¥1.65m	0.029% CN¥ 2.7m
Pi Wei	Deputy General Manager & Secretary	2.6yrs	CN¥714.90k	0.0083% CN¥ 773.6k
Zhongneng Wang	Deputy General Manager	2.6yrs	CN¥1.39m	0.026% CN¥ 2.4m
Fengping Wang	Deputy General Manager	2.6yrs	CN¥2.09m	0.020% CN¥ 1.9m
Qi Chen	Deputy General Manager	1.3yrs	no data	no data
Xiongbin Ma	Deputy General Manager	1.3yrs	no data	no data
Yuanming Huang	Deputy General Manager	1.3yrs	no data	no data

2.6yrs

Average Tenure

47yo

Average Age

Experienced Management: 300363's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Nianfeng Ju	Chairman & GM	no data	CN¥1.93m	10.8% CN¥ 1.0b
Weiqiang Yang	Non Independent Director	3.3yrs	CN¥180.00k	no data
Guohua Cao	Independent Director	4.2yrs	CN¥180.00k	no data
Hui Zeng	Employee Representative Supervisor	no data	CN¥212.80k	no data
Lin Yuan	Independent Director	2.6yrs	CN¥180.00k	no data
Jinwei Pang	Independent Director	2.6yrs	CN¥180.00k	no data
Yongqing Tan	Non-Employee Supervisory Board Chairman	no data	no data	no data
Ying Xue	Non-Independent Director	4.2yrs	CN¥180.00k	0.0027% CN¥ 252.2k
Jun Zhu	Director	1.8yrs	no data	no data
Lina Hu	Non-Independent Director	2.6yrs	CN¥180.00k	no data
Guojun Cao	Non-Independent Director	2.6yrs	CN¥180.00k	no data
Yuchen Wu	Non-Employee Supervisor	2.6yrs	no data	no data

2.6yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 300363's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Porton Pharma Solutions Management

Management criteria checks 2/4

Key information

Recent management updates

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new directors

High number of new and inexperienced directors

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Recent updates

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

New major risk - Revenue and earnings growth

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 16%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New major risk - Revenue and earnings growth

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Full year 2022 earnings released: EPS: CN¥3.70 (vs CN¥0.97 in FY 2021)

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS: CN¥0.70 (vs CN¥0.16 in 1Q 2021)

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Revenue beats expectations

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13

Investor sentiment improved over the past week

New 90-day high: CN¥39.66

Third quarter earnings released

Porton Pharma Solutions Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Market bids up stock over the past week

New 90-day high: CN¥38.90

Porton Pharma Solutions Ltd. Announces Board Changes

Earnings released

Porton Pharma Solutions Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members